XML 39 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Unaudited Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Preferred Stock [Member]
Series C-1 Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series F Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings
Beginning Balance (in shares) at Dec. 31, 2018   4,000 3,000 26,259,000    
Beginning Balance at Dec. 31, 2018 $ 35,921 $ 3,906 $ 2,737 $ 3 $ 950,258 $ (920,983)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Share-based compensation expense 6,782       6,782  
Issuance of common stock under ESPP (in shares)       52,000    
Issuance of common stock under ESPP 283       283  
Net loss (31,685)         (31,685)
Issuance of common stock for conversion of Series F Preferred Stock (in shares)     (3,000) 782,000    
Issuance of common stock for conversion of Series F Preferred Stock     $ (2,737)   2,737  
Ending Balance (in shares) at Mar. 31, 2019   4,000 0 27,093,000    
Ending Balance at Mar. 31, 2019 11,301 $ 3,906 $ 0 $ 3 959,900 (952,508)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Cumulative-effect adjustment from adoption of ASU 2018-07 (160)          
Beginning Balance (in shares) at Dec. 31, 2019   4,000 0 27,195,000    
Beginning Balance at Dec. 31, 2019 (55,990) $ 3,906 $ 0 $ 3 977,432 (1,037,331)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Share-based compensation expense $ 2,407          
Exercise of stock options for common stock (in shares) 44,258     44,000    
Exercise of stock options for common stock $ 305       305  
Issuance of common stock under ESPP (in shares)       38,000    
Issuance of common stock under ESPP 200       200  
Net loss (8,591)         (8,591)
Ending Balance (in shares) at Mar. 31, 2020   4,000 0 27,277,000    
Ending Balance at Mar. 31, 2020 (61,669) $ 3,906 $ 0 $ 3 $ 980,344 $ (1,045,922)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Cumulative-effect adjustment from adoption of ASU 2018-07 $ 0